Research Topics
| Joseph PergolizziSummaryCountry: USA Publications
| Collaborators
|
Detail Information
Publications
Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioidsJoseph V Pergolizzi
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Pain Pract 11:230-9. 2011....- Compounding pharmacies: who is in charge?Joseph V Pergolizzi
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Pain Pract 13:253-7. 2013..Moreover, clinicians should be better aware that some injectable products they use may have been prepared by a compounding pharmacy... - Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomitingJoseph V Pergolizzi
Department of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA
J Clin Anesth 24:334-45. 2012..59, 95% CI, 0.48-0.73, P < 0.001), postoperative vomiting (RR=0.68, 95% CI, 0.61-0.76, P < 0.001), and PONV (RR 0.73, 95% CI, 0.60-0.88, P = 001) in the first 24 hours after the start of anesthesia... - Current considerations for the treatment of severe chronic pain: the potential for tapentadolJoseph Pergolizzi
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Pain Pract 12:290-306. 2012..Pain relief remained stable throughout a 1-year safety study. Thus, tapentadol could possibly overcome some of the limitations of currently available analgesics for the treatment of chronic pain... - The chronic pain conundrum: should we CHANGE from relying on past history to assessing prognostic factors?Joseph Pergolizzi
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Curr Med Res Opin 28:249-56. 2012..Despite limited empirical support, chronic pain has traditionally been defined mainly on the basis of its duration, which takes no account of the causative mechanisms or its clinical significance... - Continuous multimechanistic postoperative analgesia: a rationale for transitioning from intravenous acetaminophen and opioids to oral formulationsJoseph V Pergolizzi
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Pain Pract 12:159-73. 2012..For postsurgical analgesia with any acetaminophen product, patient education is necessary to be sure that the patient does not concurrently take any over-the-counter products containing acetaminophen and accidentally exceed dose limits... - Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioidsJoseph V Pergolizzi
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Pain Pract 12:33-44. 2012.... - Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioidsJoseph V Pergolizzi
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Pain Pract 12:45-56. 2012..Patients in the study who experienced DDEs that placed them at risk for PK DDIs had significantly greater utilization rates of healthcare resources and higher associated payments in the 6-month observation period following exposure... 
Restoration of disk height through non-surgical spinal decompression is associated with decreased discogenic low back pain: a retrospective cohort studyChristian C Apfel
Perioperative Clinical Research Core, Department of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California, USA
BMC Musculoskelet Disord 11:155. 2010....
Quantifying the impact of drug-drug interactions associated with opioidsJoseph V Pergolizzi
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Am J Manag Care 17:S288-92. 2011..Clinicians often underestimate the risk of DDIs in patients using opioids. Comprehensive studies of real-world opioid utilization patterns are needed to determine the quantitative impact of opioid DDIs...- Extended-release formulations of tramadol in the treatment of chronic painJoseph V Pergolizzi
Johns Hopkins University School of Medicine, Department of Medicine, Baltimore, MD, USA
Expert Opin Pharmacother 12:1757-68. 2011..As is true for all such options, the benefits and risks must be assessed for each patient... - Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, metJoseph Pergolizzi
Johns Hopkins University, Baltimore, Maryland, USA
Pain Pract 8:287-313. 2008..Slow dose titration helps to reduce the incidence of typical initial adverse events such as nausea and vomiting. Sustained release preparations, including transdermal formulations, increase patient compliance... - Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptionsJoseph V Pergolizzi
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Pain Pract 11:325-36. 2011..When selecting an opioid analgesic to treat osteoarthritis, physicians should consider the potential for exposure of these patients to drugs that could interact unfavorably. .. - The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensusJoseph V Pergolizzi
Johns Hopkins University School of Medicine, Baltimore, MD, USA
Curr Med Res Opin 25:1517-28. 2009.... - Preliminary observations of a novel topical oil with analgesic properties for treatment of acute and chronic pain syndromesJoseph V Pergolizzi
Johns Hopkins University, Baltimore, Maryland, USA
Pain Pract 10:201-13. 2010..Several clinical trials of this oil will be reviewed... - The role of urine drug testing for patients on opioid therapyJoseph Pergolizzi
Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
Pain Pract 10:497-507. 2010..The study found motivations for urine testing and testing practices varied widely, and urine testing, despite its clinical utility, is not used consistently... - Current knowledge of buprenorphine and its unique pharmacological profileJoseph Pergolizzi
Johns Hopkins University, Baltimore, Maryland, USA
Pain Pract 10:428-50. 2010..The expert group agreed that these properties, as well as proven efficacy in severe pain and favorable tolerability, mean that buprenorphine can be considered a safe and effective option for treating chronic cancer and noncancer pain... - The societal impact of pain in the European Union: health-related quality of life and healthcare resource utilizationPaul Langley
College of Pharmacy, University of Minnesota, Minnesota, MN 55455 0343, USA
J Med Econ 13:571-81. 2010..This paper reports on the results of a series of quantitative assessments of the association of severe and frequent pain with health-related quality of life and healthcare resource utilization in five European countries... - The impact of pain on labor force participation, absenteeism and presenteeism in the European UnionPaul Langley
College of Pharmacy, University of Minnesota, Minnesota, MN 55455 0343, USA
J Med Econ 13:662-72. 2010.... - Tapentadol in the management of chronic low back pain: a novel approach to a complex condition?Joseph Pergolizzi
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
J Pain Res 4:203-10. 2011..Current evidence indicates that tapentadol's efficacy/tolerability ratio may be better than those of classical opioids. However, further research is needed to establish its role in pain management... - Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 studyAron Altorjay
Department of Surgery, St George University Teaching Hospital, Szekesfehervar, Hungary
Arch Surg 146:201-6. 2011....